Stage-dependent biomarker changes in spinocerebellar ataxia type 3

Jennifer Faber¹,², Moritz Berger³, Wilke Carlo⁴,⁵, Jeannette Hübener-Schmid⁶, Tamara Schaprian¹, Magda M Santana⁷,⁸, Marcus Grobe-Einsler¹,², Dement Onder¹,², Berkan Koyak¹,², Paola Giunt⁹,¹⁰, Hector Garcia-Moreno⁹,¹⁰, Cristina Gonzalez-Robles⁹,¹⁰,¹¹, Manuela Lima¹², Mafalda Raposo¹²,¹³, Ana Rosa Vieira Melo¹², Luís Pereira de Almeida⁷,⁸, Patrick Silva⁷,⁸,¹⁴, Maria M Pinto⁷,⁸,¹⁴, Bart P. van de Warrenburg¹⁵, Judith van Gaalen¹⁵,¹⁶, Jeroen de Vries, Jeroen¹⁷, Gulin Oz¹⁸, James M. Joers¹⁸, Matthis Synofzik⁴,⁵, Ludger Schölß⁴,⁵, Olaf Ries⁶, Jon Infante¹⁹,²⁰, Leire Manrique¹⁹, Dagmar Timmann²¹, Andreas Thieme²¹, Heike Jacobi²², Kathrin Reetz²³,²⁴, Imis Dogan²³,²⁴, Chiadikaobi Onyike²⁵, Michal Povazan²⁶, Jeremy Schmahmann²⁷, Eva-Maria Rataf²⁸, Matthias Schmid¹,³, Thomas Klockgether¹,²

Abstract

Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3) is the most common autosomal dominant ataxia. In view of the development of targeted therapies for SCA3, precise knowledge of stage-dependent fluid and MRI biomarker changes is needed.

We analyzed cross-sectional data of 292 SCA3 mutation carriers including 57 pre-ataxic individuals, and 108 healthy controls from the European Spinocerebellar ataxia type 3/Machado-Joseph Disease Initiative (ESMI) cohort. Blood concentrations of mutant ATXN3 and neurofilament light (NfL) were determined, and volumes of pons, cerebellar white matter (CWM) and cerebellar grey matter (CGM) were measured on MRI.

Mutant ATXN3 concentrations were high before and after ataxia onset, while NfL continuously increased and deviated from normal 11.9 years before onset. Pons and CWM volumes decreased, but the deviation from normal was only 2.0 years (pons) and 0.3 years (CWM) before ataxia onset. We propose a staging model of SCA3 that includes an initial asymptomatic carrier stage followed by the biomarker stage defined by absence of ataxia, but a significant rise of NfL. The biomarker stage leads into the ataxia stage, defined by manifest ataxia.

The present analysis provides a robust framework for further studies aiming at elaboration and differentiation of the staging model of SCA3.
Author affiliations:

1 German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
2 Department of Neurology, University Hospital Bonn, Bonn, Germany
3 University of Bonn, Medical Faculty, Institute for Medical Biometry, Informatics and Epidemiology
4 Division Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Germany
5 German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
6 Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
7 Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
8 Center for Innovative in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
9 Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK
10 Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK
11 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK
12 Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal
13 Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
14 Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
15 Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud university medical center
16 Department of Neurology, Rinjstate Hospital, Arnhem, The Netherlands
17 University Medical Center Groningen, Neurology
18 Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, MN, USA

19 University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain

20 Centro de investigación biomédica en red de enfermedades neurodegenerativas (CIBERNED), Universidad de Cantabria, Santander, Spain

21 Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen

22 Department of Neurology, University Hospital of Heidelberg, Germany

23 Department of Neurology, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany

24 JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, Research Centre Juelich GmbH and RWTH Aachen University, 52074 Aachen, Germany

25 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland USA

26 Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

27 Ataxia Center, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School

28 Massachusetts General Hospital, Department of Radiology, A. A. Martinos Center for Biomedical Imaging and Harvard Medical School, Charlestown, Massachusetts, USA

Correspondence to: Jennifer Faber

Full address:

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

Venusberg-Campus 1, 53127 Bonn

E-Mail: jennifer.faber@dzne.de

Running title: Biomarker changes in SCA3

Keywords: Spinocerebellar ataxia; disease modeling; biomarker
Introduction

Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3) is the most common autosomal dominantly inherited ataxia disease worldwide. It is caused by unstable expansions of polyglutamine encoding CAG repeats in the \textit{ATXN3} gene, resulting in the formation of an abnormally elongated disease protein.\textsuperscript{1} Several fluid and imaging biomarker candidates, that showed alterations before the clinical onset of ataxia have been identified in SCA3.\textsuperscript{2-7} After onset, ataxia in SCA3 takes a progressive course over an average of 20 years leading to increasing disability and premature death.\textsuperscript{8}

Targeted therapies for SCA3 are being developed, and a first safety trial of an antisense oligonucleotide (ASOs) inducing cleavage of the RNA encoding \textit{ATXN3} has been initiated in patients with SCA3 (https://clinicaltrials.gov/ct2/show/NCT05160558). In the future, preventive trials including pre-ataxic SCA3 mutation carriers will be a realistic option.\textsuperscript{9} For the design of such trials, a thorough understanding of the dynamics of the various biomarkers that reflect the cascade of pathological events associated with SCA3 is a crucial prerequisite.

We analysed a large cross-sectional dataset of SCA3 mutation carriers from the European Spinocerebellar ataxia type 3/Machado-Joseph Disease Initiative (ESMI) cohort that covers a long period of the disease course ranging from early pre-ataxic to late advanced phases. Our aim was to delineate fluid and MRI biomarker changes in relation to ataxia manifestation throughout the disease course. We concentrated on blood levels of ATXN3 and neurofilament light (NfL), as well as MRI-derived brainstem and cerebellar volumes. These markers reflect key pathological changes of SCA3 and are known to be abnormal before onset of ataxia.\textsuperscript{4-7,10-12} To assess the presence and severity of ataxia, we used the Scale for the Assessment and Rating of Ataxia (SARA).\textsuperscript{13} Our analysis allowed to propose a staging model of SCA3 based on changes of SARA and the biomarkers under study.

Materials and methods

Study participants

This prospective, longitudinal, observational cohort study is carried out at 14 sites in five European countries (Germany, Netherlands, Portugal, Spain, and United Kingdom) and the United States. Participants of the ESMI cohort undergo annual standardized assessment
including a clinical examination and biosampling. MRI is performed at 11 sites. SCA3 mutation carriers, their first-degree relatives and healthy controls are eligible for inclusion.

For this analysis, we used cross-sectional data of 292 SCA3 mutation carriers and 108 healthy controls of whom at least one fluid or MRI biomarker result was available at Jan 31, 2022. The ESMI consortium previously published individual biomarker data separately. The present analysis is largely based on these data.4-6

The study was approved by the local ethics committees. Written informed consent according to the declaration of Helsinki was obtained from all participants.

Assessments

We used the Scale for the Assessment and Rating of Ataxia (SARA)13 to assess the presence and severity of ataxia. Manifest ataxia was defined by a score of ≥ 3, the term “pre-ataxic” is used for all SCA3 mutation carriers with a SARA < 3. The cut-off value of three was defined by the mean plus 2 standard deviations in the initial validation study.14

Using a single molecule counting immunoassay, we measured plasma concentrations of expanded ATXN3.6 Serum concentrations of NfL were determined with an ultra-sensitive single-molecule array (Simoa) assay.4 One single outlier with a value of NfL 4-fold higher than all other participants was excluded.

T1-weighted MRIs were acquired using a magnetization prepared rapid gradient-echo sequence (MPRAGE, TR = 2500 ms, TE = 4.37 ms, TI = 1100 ms, flip angle = 7 deg, FOV 256 mm x 256 mm, 192 slices with a voxel size of 1 mm isotropic) on Siemens 3T scanners (Siemens Medical Systems, Erlangen, Germany). Volumes of the pons15, cerebellar white matter (CWM) and cerebellar grey matter (CGM)12 were measured and normalized by each participant's total intracranial volume.

Repeat lengths of the expanded and normal alleles were determined at the Institute for Medical Genetics and Applied Genomics of the University of Tübingen. DNA samples were available in 243 of the 292 study participants. For 43 participants, information about repeat lengths was taken from medical records. In six participants, no information about repeat lengths was available.

Age of onset was defined as the reported first occurrence of gait disturbances. For SCA3 mutation carriers, not yet experiencing gait disturbances, the age of onset was calculated on the
basis of CAG repeat length and the actual age\textsuperscript{16}. The reported age of onset was missing in 15 SCA3 mutation carriers with gait disturbances. For such cases, we calculated the age of onset based on the CAG repeat length.\textsuperscript{16}

**Statistical analysis**

Statistical analysis was carried out using R version 4.1.1 (R Core Team 2022: R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria). Descriptive analysis included the calculation of mean and standard deviation for continuous variables and frequencies (counts and percentages) for categorical variables.

Additive Gaussian regression models were used to relate fluid and MRI biomarker results in SCA3 mutation carriers to the time from ataxia onset. The functions in time were specified as a cubic P-splines with a second order difference penalty. For this, NfL concentrations and MRI volumes were z-transformed with respect to age as described before.\textsuperscript{5} Since SARA scores and ATXN3 concentrations in healthy controls are close to 0, no z-transformation was performed for these values, and the raw values were used.

Based on these regression models we defined the carrier, biomarker and ataxia stage. For a detailed description we refer to the results section. Fluid and imaging biomarker values, namely ATXN3, NfL and volumes of the pons, cerebellar white matter (CWM) and grey matter (CGM), as well as SARA sum scores in SCA3 mutation carriers were compared between the three stages using one-way ANOVA followed by pairwise comparisons using Tukey’s test, respectively.

The association between ataxia severity (assessed with SARA, dependent variable) and age, sex, CAG repeat length of the expanded allele, NfL levels, and pons, CWM and CGM volume as independent variables was investigated using a penalized linear regression model with LASSO penalty. Mutant ATXN3 was not included in the model, since it did not show marked temporal dynamics and would have substantially limited the number of cases. The optimal penalty parameter was determined by repeated ten-fold cross-validation (100 replications). A Box-Cox transformation with parameter $\lambda= 0.25$ was applied to the SARA sum score to approach normality.

**Data availability statement**
Due to the sensitive nature of the data on rare diseases, access to the data can only be granted upon reasonable request, subject to the General Data Protection Regulation (GDPR) and any other relevant data protection laws. Please contact Jennifer Faber and Thomas Klockgether (jennifer.faber@dzne.de, thomas.klockgether@ukbonn.de) to submit a data access request.

Results

Table 1 shows demographic and genetic data. MRI results, ATXN3 concentrations, and NfL levels were available in 161, 134, 327 participants, respectively, with an overlap between all three markers in 38 participants, between ATXN3 and MRI in 39, between NfL and MRI in 96, and between ATXN3 and NfL in 125 participants.

Changes of SARA scores, fluid biomarker levels, and MRI volumes of SCA3 mutation carriers in relation to the time from ataxia onset are shown in Figure 1. SARA scores were below 3 until the onset of ataxia and increased in a sigmoidal shape thereafter. Mutant ATXN3 concentrations were high with wide variation throughout the disease course, while NfL continuously increased during the pre-ataxic period and reached a plateau after ataxia onset. Overlap of the NfL 95% CIs of SCA3 mutation carriers with the interval of mean ± 2 SD of controls ended 11.9 years before onset. Pons and CWM volumes also started to decrease before ataxia onset, but the overlap of the 95% CI of SCA3 mutation carriers and the interval of mean ± 2 SD in controls ended only 2.0 years (pons) and 0.3 years (CWM) before ataxia onset. CGM volume only slightly decreased and stayed within the ± 2 SD range around the mean of controls during the entire disease course.

Based on the temporal sequence of biomarker changes, we defined the following disease stages: (i) The carrier stage includes pre-ataxic mutation carriers without significant biomarker abnormalities other than the presence of mutant ATXN3. It is defined by SARA < 3 and an NfL z-score < 2. We chose NfL as a criterion, as the preceding analysis showed that levels of NfL were the first of the studied biomarkers to rise. (ii) The biomarker stage includes pre-ataxic mutation carriers with significant biomarker changes. It is defined by SARA < 3 and an NfL z-score ≥ 2. (iii) The ataxia stage includes ataxic mutation carriers. It is defined by SARA ≥ 3 (Figure 2).

In the carrier stage, z-scores of MRI volumes of all SCA3 mutation carriers were > -2. In the biomarker stage, pons and CWM volume z-scores in 2 out of 11 (18 %) and CGM volume z-scores in 3 out of 11 (27 %) mutation carriers were ≤ -2. In the ataxia stage, NfL z-scores were
≥ 2 in 174 of 190 (92 %) mutation carries. Further, pons volume z-scores in 77 of 86 (90 %), CWM volume z-scores in 78 of 86 (91 %), and CGM volume z-scores in 26 of 86 (30 %) were ≤ -2.

Changes of SARA and the analyzed biomarkers in each stage are shown in Figure 3. Levels of mutant ATXN3 did not differ between the carrier, biomarker and ataxia stage in SCA3 mutation carriers. SCA3 mutation carriers in the biomarker stage showed by definition significantly increased NfL z-scores compared to the carrier stage, while SARA as well as pons, CWM and CGM volumes did not differ between the carrier and biomarker stages. SARA and all biomarkers except ATXN3 differed between the ataxia and carrier stage.

A regression model including age, sex, CAG repeat length of the expanded allele, NfL, and MRI volumes explained 73.9% of the variability of ataxia severity, as measured by SARA. The order of selection into the penalized model, reflecting the contribution to the model from high to low, was CWM volume, age, pons volume, NfL, CAG repeat length, and CGM. A model that did not include NfL and MRI volumes explained only 60.4% of SARA.

**Discussion**

Using cross-sectional data from 292 SCA3 mutation carriers from the ESMI cohort, we estimated the temporal order and extent of fluid biomarker and MRI volume changes along the disease course of SCA3. Based on the observed biomarker changes and manifestation of ataxia, we drafted a staging model of SCA3 that includes an initial asymptomatic carrier stage followed by the biomarker stage defined by absence of ataxia, but a significant rise of NfL. The biomarker stage leads into the ataxia stage, which is defined by manifest ataxia.

The present analysis is limited by its cross-sectional design. Therefore, supplementation by longitudinal data is needed. However, even with long-term studies only short sections of the entire disease course that starts before ataxia onset and spans over approximately 40 years can be covered. Although ESMI is one of the largest SCA3 cohorts worldwide, the amount of biomarker data available for analysis was limited. To improve statistical power in future analyses, merging of ESMI data with data from other cohorts is mandatory.

Plasma concentrations of the elongated disease protein ATXN3 were high detectable throughout the entire disease course and did not differ between the different stages. This is best explained by the fact that elevation of mutant ATXN3 levels is the direct consequence of the gene mutation causing SCA3. Nature and extent of the changes characterize mutant ATXN3 as
a trait rather than a progression biomarker. We therefore did not use ATXN3 as a criterion for the definition of disease stages.

The rise of NfL preceded ataxia onset by 11.9 years. This agrees with previous reports on NfL data of ESMI participants, as well as findings in other cohorts. As the rise of NfL marks the first currently detectable damage to the nervous system in SCA3, we used NfL as a criterion to define the biomarker stage in pre-ataxic individuals.

While NfL is supposed to reflect the rate of degeneration, MRI regional volume loss rather represents the cumulated result of degeneration explaining why volume loss followed the rise of NfL, and why MRI volumes did not differ between the carrier and biomarker stage on a group level. Nevertheless, pons and CWM volumes showed a continuous decrease and deviated from normal 2.0 and 0.3 years before ataxia onset. Consequently, they may be considered for the identification of mutation carriers close to the clinical onset. CGM volume loss overall was less pronounced and most prominent in the ataxia stage. These observations are in line with autopsy findings that show, unlike most other SCAs, relative sparing of cerebellar cortex in SCA3. The strong involvement of the CWM volume corroborates previous findings of prominent white matter loss in patients with SCA3 and is in line with reports of early oligodendrocyte pathology in mouse models of SCA3. Pons volume showed an almost linear decline along the entire disease range, denoting it as a potential marker of disease progression.

A previous study in SCA3 patients showed that ataxia severity, as measured by SARA, can be predicted by CAG repeat length and age. The present data show that the accuracy of the prediction was substantially improved by adding NfL levels as well as pons and CWM volumes to the prediction model underlining the biological relevance of these markers.

The present data allowed for the first time to draft of a data-driven model of disease stages for SCA3. While the disease was previously divided into a pre-ataxic and ataxic stage, we propose a more differentiated model similar to that recently presented for Huntington’s disease (HD). We defined the onset of biomarker stage by the rise of NfL. However, it is possible that changes of other biomarkers indicating incipient damage to the nervous system precede the rise of NfL. Further studies including additional fluid and imaging biomarker data, such as MR spectroscopy and diffusion imaging, may allow to further subdivide the biomarker stage. In the present model, we have not introduced a clinical sign or symptom stage preceding the final clinical stage like in the HD model. Yet, this might be considered reasonable, since such signs and symptoms, like oculomotor dysfunction, have been described in pre-ataxic SCA3 mutation
carriers. The ataxia stage has previously been subdivided into three stages defined by milestones of gait deterioration leading to further differentiation of the model.

The present staging model of SCA3 is to be considered as first proposal that needs to be further refined and extended based on more data and broad consensus. Nevertheless, it provides a robust framework for further studies aiming at elaboration and differentiation of the model.

Acknowledgements

TK, MS, LS, JI, BvdW are members of the European Reference Network for Rare Neurological Diseases (ERN-RD, project number 739510). The ESMI consortium acknowledges Ruth Hossinger for the project management of the ESMI project and for all contributions made towards the success of this project.

Funding information

This publication is an outcome of ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The project is supported through the following funding organisations under the aegis of JPND: Germany, Federal Ministry of Education and Research (BMBF; funding codes 01ED1602A/B); Netherlands, The Netherlands Organisation for Health Research and Development; Portugal, Fundação para a Ciência e Tecnologia (funding code JPCOFUND/0002/2015); United Kingdom, Medical Research Council (MR/N028767/1). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643417.

On the Azores ESMI Network is currently supported by the Regional Government (Fundo Regional para a Ciência e a Tecnologia-FRCT), under the PRO-SCIENTIA program.

At the US sites this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS080816. The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and S10 OD017974 grant.
JF received funding as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. MR is supported by FCT (CEECIND/03018/2018). BvdW receives funding from ZonMw, NWO, Gossweiler Foundation, Brugling Fonds, Radboudmc, Hersenstichting. DT received research grants from the Deutsche Forschungsgemeinschaft (DFG), European Union (EU), the Bernd Fink Foundation and the Once Upon a Time Foundation. CO receives funding from NINDS #U01 NS104326; National Ataxia Foundation; Robert and Nancy Hall Brain Research Fund. JS was supported in part by the National Ataxia Foundation and the MINDlink Foundation. JJ received grant support from NIH and Friedrich’s Ataxia Research Alliance (FARA). AT received research grants from the University Medicine Essen Clinician Scientist Academy (UMEA)/Deutsche Forschungsgemeinschaft (DFG, grant number: FU356/12-1), the Mercator Research Foundation, the German Heredoataxia Society (DHAG) and “Freunde und Förderer der Neurologie der Universität medizin Essen”. At the Portuguese sites, MMS and LPA received funding from European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Program; through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation, and Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia, under the projects: CENTRO-01-0145-FEDER-181240, 2022.06118.PTDC, UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, ViraVector (CENTRO-01-0145-FEDER-022095), ReSet – IDT-COP (CENTRO-01-0247-FEDER-070162), Fighting Sars-CoV-2 (CENTRO-01-01D2-FEDER-000002), BDforMJD (CENTRO-01-0145-FEDER-181240), ModelPolyQ2.0 (CENTRO-01-0145-FEDER-181258), MJDEDIT (CENTRO-01-0145-FEDER-181266); ARDAT under the IMI2 JU Grant agreement No 945473 supported by the European Union’s H2020 programme and EFPIA; by the American Portuguese Biomedical Research Fund (APBRF) and the Richard Chin and Lily Lock Machado-Joseph Disease Research Fund. PS (SFRH/BD/148451/2019) and MMP (2022.11089.BD) are supported FCT.

PS was supported by Portuguese Foundation for Science and Technology (FCT) under the fellowship grant SFRH/BD/148451/2019. CW was supported by the Clinician Scientist Program of the Medical Faculty Tübingen (480-0-0).

**Competing interests**

GO consults for IXICO Technologies Limited, which provides neuroimaging services and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for SCAs, and
receives research support from Biogen, which develops therapeutics for SCAs. MS has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, GenOrph, and AviadoBio, all unrelated to the present manuscript. LS received consultancy honoraria from Vico Therapeutics and Novartis unrelated to the present manuscript. LPA research group has private funding from PTC Therapeutics, Unique, Wave life Sciences, Servier, Blade Therapeutics and Hoffmann-La Roche AG outside the submitted work.

Figure Legends

Figure 1: Scale for the Assessment and Rating of Ataxia (SARA) scores, fluid and MRI biomarker data in SCA3 mutation carriers in relation to time of ataxia onset. Data were analyzed with additive Gaussian regression on a time scale defined by ataxia onset. The time of ataxia onset is indicated with a vertical dashed line in all graphs. The estimated 95% CIs are shown by the shaded areas around the curves.

(A) SARA sum score. The SARA cut-off of 3 defining manifest ataxia is given as a dashed horizontal line.

(B) Plasma concentrations of elongated ATXN3. Data are given in ng/ml.

(C) Serum concentrations of neurofilament light (NfL), MRI volumes of the pons, cerebellar with matter (CWM) and grey matter (CGM). Data were z-transformed in relation to healthy controls of same age. Y-axis of volume values is inverted for better comparability of volume loss and NfL increase. Mean of healthy controls is given as a horizontal line, the 1 SD range by dashed, and the 2 SD range by dotted lines.

Figure 2: Staging model of SCA3. Proposed staging model of SCA3 based on the studied fluid and MRI biomarker data. The model includes an initial asymptomatic carrier stage followed by the biomarker stage defined by absence of ataxia, but a significant rise of NfL. The biomarker stage leads into the ataxia stage, which is defined by manifest ataxia. Following previous suggestions, the ataxia stage is further subdivided into three substages defined by milestones of gait deterioration.30

Figure 3 Scale for the Assessment and Rating of Ataxia (SARA) scores, fluid and MRI biomarker data in the carrier, biomarker and ataxia stage of SCA3. Data were analyzed with one-way ANOVA followed by pairwise comparisons using Tukey’s test * p<0.01;

References


Table 1 Demographic and genetic data of study participants

<table>
<thead>
<tr>
<th></th>
<th>N (male/female)</th>
<th>Age (years)</th>
<th>Age at ataxia onset (years)</th>
<th>Time from ataxia onset (years)</th>
<th>Length of expanded CAG repeat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy controls</td>
<td>108 (49/59)</td>
<td>46.1 (14.0)</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Pre-ataxic SCA3 mutation carriers</td>
<td>57 (22/35)</td>
<td>35.5 (9.0)</td>
<td>43.2 (9.1)</td>
<td>-7.7 (8.0)</td>
<td>68.2 (3.7)</td>
</tr>
<tr>
<td>Ataxic SCA3 mutation carriers</td>
<td>235 (126/109)</td>
<td>51.3 (11.3)</td>
<td>39.9 (10.5)</td>
<td>11.3 (10.5)</td>
<td>68.8 (4.2)</td>
</tr>
</tbody>
</table>

Age, age at ataxia onset, time from ataxia onset, and length of expanded CAG repeat are given as mean (SD). n.a. – not applicable.
Figure 1: Scale for the Assessment and Rating of Ataxia (SARA) scores, fluid and MRI biomarker data in SCA3 mutation carriers in relation to time of ataxia onset. Data were analyzed with additive Gaussian regression on a time scale defined by ataxia onset. The time of ataxia onset is indicated with a vertical dashed line in all graphs. The estimated 95% CIs are shown by the shaded areas around the curves. (A) SARA sum score. The SARA cut-off of 3
defining manifest ataxia is given as a dashed horizontal line. (B) Plasma concentrations of elongated ATXN3. Data are given in ng/ml. (C) Serum concentrations of neurofilament light (NfL), MRI volumes of the pons, cerebellar with matter (CWM) and grey matter (CGM). Data were z-transformed in relation to healthy controls of same age. Y-axis of volume values is inverted for better comparability of volume loss and NfL increase. Mean of healthy controls is given as a horizontal line, the 1 SD range by dashed, and the 2 SD range by dotted lines.
Figure 2: Staging model of SCA3. Proposed staging model of SCA3 based on the studied fluid and MRI biomarker data. The model includes an initial asymptomatic carrier stage followed by the biomarker stage defined by absence of ataxia, but a significant rise of NfL. The biomarker stage leads into the ataxia stage, which is defined by manifest ataxia. Following previous suggestions, the ataxia stage is further subdivided into three substages defined by milestones of gait deterioration.\(^3\)

Figure 3: Scale for the Assessment and Rating of Ataxia (SARA) scores, fluid and MRI biomarker data in the carrier, biomarker and ataxia stage of SCA3. Data were analyzed with one-way ANOVA followed by pairwise comparisons using Tukey’s test * p<0.01; **p<0.001. NfL - neurofilament light, CWM – cerebellar white matter, CGM – cerebellar grey matter, eTIV – estimated intracranial volume.